Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combined Treatment Approach Increases Survival In Prostate Cancer

05.04.2005


New study shows combination of radiotherapy and hormone therapy extends life expectancy.



Men with prostate cancer treated with the combined therapies had a significantly higher chance of living for more than 10 years than those on radiotherapy alone. This was one of the main results published today in the International Journal of Radiation Oncology, Biology and Physics (IJROBP) by the independent Radiation Oncology Group (RTOG).

Goserelin belongs to a class of drugs called Luteinizing Hormone-Releasing Hormone agonist (LHRHa). This therapeutic modality works by inhibiting the production of the male hormone, testosterone.


The research also showed that by treating men with goserelin and radiotherapy, the chances of preventing the disease from coming back were improved by 60 percent compared to men who only received radiotherapy.1

Another study published this month in the British Journal of Urology International (BJUi) confirmed that these benefits were not seen in all LHRHas. Experts examined all LHRHas medications, but goserelin has been proven to be the only LHRHa providing proven benefit in terms of delaying progression and improving survival.

Mr Amir Kaisary, Consultant Urologist, Royal Free Hospital, London believes the RTOG’s publication is a major step forward in increasing the amount of attention being given to prostate cancer, which has always struggled to achieve the levels of public awareness of some other cancers.

‘Studies, such as the one published today in the IJROBP, are proving that surgical castration and radiotherapy are not the only treatments available for men with prostate cancer. An increasing amount of evidence shows that hormonal therapy, used either alone or with radiotherapy, offers significant benefits for men with prostate cancer, when offered in the appropriate patients.’

The study published in the IJROBP observed nearly 1,000 men with locally advanced prostate cancer over a 10 year period. The aim of the research was to determine how effective goserelin was when used with radiotherapy to treat men with locally advanced prostate cancer. This group of prostate cancer patients is where the cancer is no longer contained within the prostate gland as at the early stages of the disease.

The Department of Health has recognised the benefits of hormonal therapies because of studies such as the one published in the IJROBP. It has issued guidelines supporting the treatment of men with locally advanced prostate cancer using radiotherapy and a hormonal therapy. Anti-androgens are another type of hormonal therapy which can also be used to treat locally advanced prostate cancer. Anti-androgens block the biochemical transformation of androgens (the main one is testosterone) to the active form which stimulate the growth of prostate cancer tumours. Anti-androgens are increasingly being used by clinicians because they do not affect men’s physical strength, sexual interest or increase the risk of bone fractures. These are side effects which are associated with LHRHa therapy.

It is important that men with prostate cancer, when possible, are fully informed about the different side effects and can discuss with their doctor which treatment is the most suitable for their lifestyle and individual needs.

Tara Breen | alfa
Further information:
http://www.hillandknowlton.com

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>